This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (11) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Klein, R. D. Articles by Geary, T. G. Search for Related Content PubMed Articles by Klein, R. D. Articles by Geary, T. G. Social Bookmarking                         What's this?

Recombinant Microorganisms as Tools for High Throughput Screening for Nonantibiotic Compounds

Animal Health Discovery Research, Pharmacia & Upjohn Co., Kalamazoo, Michigan 49007

Timothy G. Geary

Animal Health Discovery Research, Pharmacia & Upjohn Co., Kalamazoo, Michigan 49007

Microorganisms were among the first tools used for the discovery of biologically active compounds. Their utility reached a zenith during the era of antibiotic development in the 1950s and 1960s, then declined. Subsequently, a substantial role for microorganisms in the pharmaceutical industry developed with the realization that microbial fermentations were intriguing sources of nonantibiotic natural products. From recombinant DNA technology emerged another important role for microorganisms in pharmaceutical research: the expression of heterologous proteins for therapeutic products or for in vitro high throughput screens (HTSs). Recent developments in cloning, genetics, and expression systems have opened up new applications for recombinant microorganisms in screening for nonantibiotic compounds in HTSs. These screens employ microorganisms that depend upon the function of a heterologous protein for survival under defined nutritional conditions. Compounds that specifically target the heterologous protein can be identified by measuring viability of the microorganism under different nutrient selection. Advantages of this approach include a built-in selection for target selectivity, an easily measured end point that can be used for a multitude of different targets, and compatibility with automation required for HTSs. Mechanism-based HTSs using recombinant microorganisms can also address drug targets that are not readily approachable in other HTS formats, including certain enzymes; ion channels and transporters; and protein::protein, protein::DNA, and protein::RNA interactions.

Journal of Biomolecular Screening, Vol. 2, No. 1, 41-49 (1997)
DOI: 10.1177/108705719700200108


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M.-H. Beydon, A. Fournier, L. Drugeault, and J. Becquart Microbiological High Throughput Screening: An Opportunity for the Lead Discovery Process J Biomol Screen, February 1, 2000; 5(1): 13 - 21. [Abstract] [PDF]